Protagonist Therapeutics PTGX Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Bristol-Myers SquibbBMY

$207M+6.7%

IncyteINCY

$5.59M-9.5%

Disc MedicineIRON

$419K-12.5%

Kymera TherapeuticsKYMR

$12.12M+3.0%

Apogee Therapeutics, Inc.APGE

$3.14M-21.1%

Oruka Therapeutics, Inc.ORKA

$680K+140%

FAQ

What is Protagonist Therapeutics's operating lease liabilities (current)?

Protagonist Therapeutics (PTGX) reported operating lease liabilities (current) of $2.4M in Q2 2026.

How has Protagonist Therapeutics's operating lease liabilities (current) changed year-over-year?

Protagonist Therapeutics's operating lease liabilities (current) increased by 10.3% year-over-year, from $2.17M to $2.4M.

What is the long-term trend for Protagonist Therapeutics's operating lease liabilities (current)?

Over 5 years (2020 to 2025), Protagonist Therapeutics's operating lease liabilities (current) has grown at a 9.4% compound annual growth rate (CAGR), from $1.46M to $2.28M.

What does operating lease liabilities (current) mean?

The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.